trending Market Intelligence /marketintelligence/en/news-insights/trending/V5JrusEkyEVTa1mWvAJ25Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

AstraZeneca-Merck's Lynparza extends patients' lives in prostate cancer study

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

AstraZeneca-Merck's Lynparza extends patients' lives in prostate cancer study

AstraZeneca PLC and Merck & Co. Inc. said Lynparza succeeded in extending the lives of certain prostate cancer patients without their disease worsening, meeting the primary goal in a late-stage study.

The phase 3 trial, known as PROfound, evaluated the efficacy and safety of Lynparza in treating patients whose castration-resistant prostate cancer had spread to other parts of the body and had the homologous recombination repair gene mutation, or HRRm.

These patients had their condition worsen even after receiving new hormonal anticancer treatments, including prostate cancer medicines Xtandi, or enzalutamide, by Japan's Astellas Pharma Inc. and Pfizer Inc., and Johnson & Johnson's Zytiga, also known as abiraterone.

Results showed that Lynparza helped patients with mutations in their BRCA1/2 or ATM genes live longer without radiographic progression, compared to Xtandi or Zytiga.

AstraZeneca said PROfound's full data will be presented at a forthcoming medical meeting.

Lynparza, or olaparib, belongs to a class of medicines known as PARP inhibitors, which work by preventing the PARP protein in cancer cells from repairing their damaged DNA, causing the cancer cells to die.

The drug is already approved as maintenance therapy for certain ovarian cancer patients in the EU, U.S. and Japan. In the U.S., Lynparza is also approved to treat patients with BRCA-mutated breast cancer.

The companies intend to explore additional trials for Lynparza in prostate cancer, including the ongoing PROpel phase 3 study evaluating a combination of Lynparza and Zytiga as the initial treatment of castration-resistant prostate cancer that has spread across the body.

U.K's AstraZeneca and Kenilworth, N.J.-based Merck are developing Lynparza under an $8.5 billion collaboration agreement signed in 2017.